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INTRODUCTION
Until recently, the Durie Salmon (DS) staging system was
primarily used in patients with multiple myeloma (MM) (1).
This staging system was designed according to cell mass, uti-
lizing hemoglobin, serum calcium, lytic bone lesions, and M
component production rates as measurements, with each stage
divided into A and B subgroups according to renal function.
More recently, the Southwest Oncology Group (SWOG)
introduced a new staging system with beta 2-microglobulin
(S 2M) and albumin as prognostic factors (2). The SWOG
staging system has been regarded as an easy, as well as good
indicator of event-free survival, first-year mortality, and long-
term survival. However, the SWOG system still requires more
time and practice until it becomes the standard method.
S 2M, which is thought to reflect known tumor cell bur-
den, has been regarded as the most important prognostic
factor in MM. Although S 2M concentration is influenced
by kidney function, multivariate analysis showed that it re-
mains an independent prognostic factor after correction for
serum creatinine concentration (3-7).
However, in patients with mild to moderate renal insuffi-
ciency, S 2M may be a better indicator of glomerular filtra-
tion rate (GFR) than serum creatinine (8, 9). We therefore
compared S 2M with 24 urinary Ccr as prognostic factors in
MM patients, and determined the significance of 24 hr urinary
creatinine clearance (Ccr) in the staging of patients with MM. 
MATERIALS AND METHODS
Subjects
We retrospectively reviewed the records of all 268 symp-
tomatic MM patients admitted and newly diagnosed at Asan
Medical Center, Seoul, Korea, from 1 January 1996 to 30
November 2003. The 24-hr urinary Ccr was available at the
time of diagnosis for 170 of these symptomatic MM patients,
and these 170 patients were enrolled into the study. Survival
time was followed until 30 April 2005. 
All the patients had symptomatic MM in accordance with
the diagnostic criteria of the International Myeloma Working
Group (2003) (11). These criteria are defined as: 1) M-pro-
tein in serum and/or urine; 2) bone marrow (clonal) plasma
cells or plasmacytomas; 3) related organ or tissue impairment
(end organ damage, including bone lesions); and 4) no min-
imal level of clonal bone marrow plasma cells.
Patients with nonsecretory myeloma, smoldering multiple
myeloma, POEMS (polyneuropathy, organomegaly, endocri-
nopathy, monoclonal gammopathy, and skin changes), plas-
ma cell leukemia, light chain deposit disease, MGUS (mon-
oclonal gammopathy of undermined significance), extra-
medullary plasmacytoma, a combination of other malignan-
cies, severe trauma were excluded. 
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Comparison of Serum Beta 2-Microglobulin and 24 hour Urinary 
Creatinine Clearance as a Prognostic Factor in Multiple Myeloma
A new staging system for multiple myeloma (MM) has utilized serum concentrations
of beta 2-microglobulin (S 2M) and albumin as important prognostic factors for sur-
vival. Since S 2M is an indicator of glomerular filtration rate, we compared the prog-
nostic values of S 2M and 24-hr urinary creatinine clearance (Ccr) in patients with
MM. We retrospectively reviewed the records of 170 MM patients from January
1996 to November 2003 whose 24-hr urinary Ccr was available at the time of diag-
nosis. We found that pretreatment S 2M was inversely related to Ccr (Spearman’s
correlation coefficient=-0.787). In univariate analysis, the hazard ratio (HR) of death
was 1.043 (p<0.001) for S 2M and 0.985 (p<0.001) for Ccr. Multivariate analysis
showed that S 2M (HR 1.030, p=0.010) and Ccr (HR 0.993, p=0.059) were signifi-
cant prognostic factors in patients’ survival. In conclusion, 24-hr urinary Ccr may
be utilized for staging of patients with MM.
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Parameters
We investigated age, sex, heavy chain types, light chain
types, Durie-Salmon stage, S 2M, hemoglobin, serum cal-
cium, serum albumin, serum creatinine, and 24 hr urine cre-
atinine clearance before chemotherapy. S 2M was measured
by a radioimmunoassay with 125I- labeled beta 2-microglob-
ulin.
Treatment
Whereas patients received various treatments, they could
be divided into 3 groups; those who received conservative
treatment (no treatment or dexamethasone [20 mg/m2 oral-
ly] only), those who received conventional chemotherapy (e.g.,
VAD, MP, high dose cytoxan plus predinisolone, and thalido-
mide plus dexamethasone regimens), and those who received
autologous stem cell transplantation.
The MP regimen consisted of melphalan (8 mg/m2) and
prednisolone (60 mg/m2) for 4 days; the VAD regimen con-
sisted of vincristine (0.4 mg), doxorubicin (9 mg/m2) for 4
days, and dexamethasone (40 mg) for 12 days. The high dose
cytoxan plus prednisolone regimen consisted of cytoxan (400
mg/m2) for 1 day and prednisolone (40 mg/m2) for 7 days
and was a variant of the VBMCP (vincristine, BCNU, mel-
phalan, cytoxan, prednisolone) regimen. The thalidomide
plus dexamethasone regimen consisted of 200 mg thalido-
mide orally per day plus 5 to 10 mg dexamethasone intra-
venously 4 times per day. 
Survival time
Medical records were used to collect data. Interviews with
patients’ families by telephone and data from the hospital
network connected to the Korean National Statistical Office
were also utilized to determine the patient survival times. 
Staging system
Patients were divided depending on DS stage, which was
assigned by physicians who first examined them (1). Then,
they were resorted by SWOG staging system according to
S 2M and albumin concentrations (2).
SWOG stage 1 was defined as S 2M <2.5 mg/L; stage 2
as 2.5 mg/L ≤S 2M <5.5 mg/L; stage 3, S 2M ≥5.5 mg/
L and serum albumin ≥3.0 g/dL; and stage 4, S 2M ≥5.5
mg/L and albumin <3.0 g/dL.
During the course of this study, we formulated a new ex-
perimental staging system based on 24 hr urinary Ccr and
serum albumin. In this system, stage 1 defined as Ccr ≥90
mL/min; stage 2 as 90 mL/min >Ccr ≥30 mL/min; stage 3
as Ccr <30 mL/min and albumin ≥3.0 g/dL; stage 4 as Ccr
<30 mL/min and albumin <3.0 g/dL. 
Statistical analysis
SPSS (version 11.0) was used to determine the means and
standard deviations and medians of patient characteristics of
patients and laboratory findings. One-way ANOVA and
Student’s t test were used to compare mean Ccr according
to heavy or light chain types. An interactive graph of Ccr
and S 2M was drawn using a scatter plot and a logarithmic
estimated curve. 
The Kaplan-Meier method was utilized for survival anal-
ysis with log rank test; statistical significance was defined as
pvalue less than 0.05.
The Cox proportional hazard model was employed for uni-
variate analysis and multivariate analyses to confirm the sig-
nificance of risk factors of death. In multivariate analysis, we
used eliminated variables stepwise (backward) by a signifi-
cance of less than 10%.
RESULTS
Study population
From 1 January 1996, through 30 November 2003, 289
patients with plasma cell disorders were admitted to our Cen-
ter. Among them, there were 268 symptomatic MM patients.
We excluded 14 patients with other monoclonal gammopa-
thies and 7 patients with combining other malignancy or severe
trauma. Gammopathies other than symptomatic multiple
myeloma were 3 MUGS, 2 plasma cell leukemia, 2 smolder-
ing MM, 2 nonsecretory MM, 1 extramedullary plasmacy-
toma, 1 multiple solitary plasmacytoma, and 3 POEMS. As
to 170 patients, 24-hr urinary creatinine clearance was avail-
able at the time of diagnosis. Baseline characteristics and lab-
oratory findings at the time of diagnosis are shown in Table 1.
Table 2 shows the mean Ccr of each type. The mean Ccr
in patients with free light chain was lower than those of the
heavy and light chain type groups. Mean Ccr of patients with
free light chain was 36.2 mL/min, whereas those of patients
with IgG type and IgA were 54.9 mL/min and 62.2 mL/min
(p=0.005), respectively. However, mean S 2M of patients
Mean±SD
or Median (Range) 
(n=170)
Age (yr) 60.0 (29-80)
Sex (male:female) 107:63 
Hemoglobin (g/dL) 9.1±2.3 
Serum calcium (mg/dL) 9.5±1.8 
Serum creatinine (mg/dL) 1.5 (0.5-17.6) 
Serum beta 2-microglobulin ( g/mL) (n=167) 5.5 (1.2-48.4) 
Serum albumin (g/dL) 3.2±0.8 
Creatinine clearance (mL/min) 47.8 (0.2-140.7) 
Table 1. Baseline characteristics of the patientsCreatinine Clearance in Multiple Myeloma 641
according to heavy chain types was not significantly differ-
ent (p=0.156).
Of the 170 patients, 28 patients were managed conserva-
tively, 92 patients were treated with conventional chemother-
apy, and 50 patients received high-dose chemotherapy with
autologous stem cell transplantations. The first-line chemo-
therapy regimens consisted of VAD in 94 patients, MP in 41,
cytoxan plus prednisolone in 4, thalidomide plus dexametha-
sone in 1. The chemotherapy regimen was unidentified in 2
patients.
We could definitively identify cause of death only if patients
died in hospital, although we attempted to interview by tele-
phone family members of patients who died outside of hos-
pital to exclude death by accidental trauma. Of the 51 patients
who died in hospital, 28 died of sepsis, 9 of respiratory fail-
ure, 4 of heart failure, 2 of major bleeding, 1 of arrhythmia,
3 of acute renal failure, 1 of acute myocardial infarction, 1 of
subdural hemorrhage, and 2 of hepatic failure.
Among the 268 symptomatic MM patients, only 3 patients
had hemodialysis before diagnosis because of acute renal fail-
ure; these patients did not have any other specific etiology,
such as diabetes mellitus or hypertension. In all 3 persons,
Ccr was measured at diagnosis, and all 3 were enrolled in this
study.
Univariate and multivariate analysis
Univariate analysis showed that age, serum calcium, serum
creatinine, S 2M, Ccr, free light chain type, and treatment
modalities were significant prognostic factors, using both the
continuous and dichotomous methods (Table 3). The conser-
vative management group had a shorter life expectancy than
both the conventional chemotherapy group (hazard ratio [HR]
2.021, p=0.004) and the autologous transplantation group (HR
9.020, p<0.001). However, S 2M concentration was not sig-
nificant in univariate analysis of 104 patients with Ccr ≥30
mL/min (HR 1.001, p=0.982) (Table 4).
Multivariate analysis of prognostic factors using the Cox
proportional hazard model showed that serum S 2M, crea-
tinine clearance, and treatment modalities were significant
prognostic factors in continuous method (Table 6). Ccr was
of borderline significance and was not eliminated by back-
ward stepwise calculation if p=0.10. Using the dichotomous
method, however, the result was somewhat different. If the
Ccr cut-off value was 30 mL/min and that of S 2M was 5.5
mg/L, Ccr and treatment were significant, but S 2M concen-
tration was not. This discrepancy was due to the close rela-
tionship of S 2M and Ccr, making it difficult to determine
a standard cutoff value using the dichotomous method.
Ccr
No. (mean±SD) 
(mL/min)
S 2M
No. (mean±SD) 
( g/mL)
Heavy chain
IgG 68 54.9±37.9 67 9.9±11.4
IgA 36 62.2±35.7 36 8.1±9.2
Free light chain  50 36.2±31.0* 48 13.3±11.4
IgD 14 50.3±36.7 14 10.5±8.2
IgM 1 (102.6) 1 (2.6)
biclonal 1 (86.2) 1 (4.1)
p=0.005 p=0.156
Light chain
�
Lambda 86 50.1±37.8 84 10.5±10.6
Kappa 83 51.9±35.7 82 10.4±11.1
p=0.751 p=0.961
*p<0.05 between patients with IgG type and free light chain type, or
between IgA type and free light chain type, 
� One with only IgG heavy
chain type was excluded.
Table 2. Types of heavy chains and light chains
Continuous Dichotomous
HR, p value Cutoff
value 
HR, p value
Age (yr) 1.038, p<0.001 ≥60   1.972, p<0.001
<60  
Sex (male:female) Male 1.075, p=0.711 
female NS
Hemoglobin (g/dL) 0.954, p=0.259  ≥9.0 0.850, p=0.386 
NS <9.0 NS
Serum calcium  1.106, p=0.026 ≥10.0 1.524, p=0.045
(mg/dL) <10.0
Serum creatinine 1.101, p<0.001 ≥1.5 2.077, p<0.001
(mg/dL) <1.5
Serum beta 2- micro-  1.043, p<0.001 ≥5.5 2.097, p<0.001
globulin ( g/mL) <5.5
Serum albumin (g/dL) 0.916, p=0.469  ≥3.0 0.987, p=0.944 
NS <3.0 NS
Creatinine clearance 0.985, p<0.001 ≥30 0.361, p<0.001
(mL/min) <30
Heavy chain type* Only light 1.525, p=0.032
Heavy and 
light chain
Light chain type  Kappa 0.753, p=0.135 
Lambda NS
Treatment modalities p<0.001
HR, hazard risk of death; NS, not significant.
*heavy chain type, Free light chain type vs. both heavy and light chain
type.
Table 3. Hazard ratio in univariate analysis 
Continuous Dichotomoud
HR, p value Cutoff
value 
HR, p value
S 2M ( g/mL) 1.001, p=0.982  ≥5.5 1.114, p=0.736
<5.5
Ccr (mL/min) 0.987, p=0.015 ≥90 0.499, p=0.034
<90 
S 2M, Serum beta 2-microglobulin; Ccr, Creatinine clearance; HR, haz-
ard risk of death.
Table 4. Hazard ratio in univariate analysis if Ccr ≥30 mL/min642 J.-P. Yun, C. Suh, E. Lee, et al.
Correlation of beta 2-microglobulin and creatinine clearance
When we drew a scatter plot of S 2M and Ccr prior to the
start of chemotherapy (Fig. 1), we found that pretreatment
S 2M was inversely related to Ccr (Spearman’s correlation
efficient -0.787, p<0.001).
Stage
Fig. 2 shows survival curves relative to DS stage and SWOG
stage. Because we enrolled only patients whose DS stage was
recorded by doctors at the time of diagnosis, the total num-
ber according to DS stage was 147 (95 dead, 52 alive). Because
S 2M was not checked in 3 patients in the study group, the
total number according to SWOG stage was 167 (112 dead,
55 alive).
Median overall survival times according to DS stage were
919 days for stage 1 (n=11), 1011 days for stage 2 (n=17),
925 days for stage 3A (n=66), and 380 days for stage 3B (n=
53).
Median survival times according to SWOG stage were
1475 days for stage 1 (n=18), 917 days for stage 2 (n=65),
453 days for stage 3 (n=57), and 152 days for stage 4 (n=
27) (log rank test <0.0001).
Possible staging system
Univariate analysis showed that, as Ccr increased, patient
Continuous
Hazard ratio Confidence interval Significance
Dichotomous*
Hazard ratio Confidence interval Significance
S 2M 1.030 1.007-1.053 p=0.010 Ccr ≥30 0.403 0.275-0.591 p<0.001
Ccr 0.993 0.986-1.000 p=0.059
� Treatment
�1),3) 7.945 4.052-15.577 p<0.001
Treatment
�1),3) 8.642 4.389-17.018 p<0.001 Treatment
�2),3) 3.717 2.147-6.435 p<0.001
Treatment
�2),3) 3.866 2.210-6.760 p<0.001
Table 5. Multivariate analysis by Cox proportional hazard model (backward)
�
Borderline significant and not eliminated backward stepwise calculations at a significance of 10%; 
�
Treatments; 1) Conservative management, 2) Con-
ventional chemotherapy, and 3) Autologous stem cell transplantation.
*Dichotomous: Cutoff values were Ccr ≥30 or <30 mL/min and S 2M ≥5.5 or <5.5  g/mL. 
Dichotomous results could not be accepted with confidence because the change in cutoff value of Ccr led to different outcomes. For example, if the
cutoff value of Ccr was ≥50 or <50 mL/min and if S 2M ≥5.5 or <5.5  g/mL, S 2M, treatment modalities, heavy chain type, serum calcium became
significant prognostic factors. This result might be caused by the close relationship between S 2M and Ccr.
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Fig. 1. Relationship of beta 2-microglobulin and 24 hr urinary cre-
atinine clearance before chemotherapy.
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Fig. 2. Survival curves according to DS stage (A) and SWOG stage
(B) with serum beta 2-microglobulin and serum albumin.
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censored
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A
Bsurvival time increased. Furthermore S 2M was closely relat-
ed with Ccr. We therefore formulated a new staging system
based on Ccr instead of S 2M, plus serum albumin (Fig. 3).
According to this system, stage 1 is Ccr ≥90 mL/min; stage
2 is 90 mL/min > Ccr ≥30 mL/min; stage 3 is Ccr <30 mL/
min and albumin ≥3.0 g/dL; stage 4, Ccr <30 mL/min and
albumin <3.0 g/dL.
Applying this system, we found that 30 patients (12 dead,
18 alive) were stage 1, 74 (44 dead, 30 alive) were stage 2,
46 (42 dead, 4 alive) were stage 3, and 20 (17 dead, 3 alive)
were stage 4.
According to this staging system, the median survival times
were 1,475 days for stage 1, 889 days for stage 2, 339 days for
stage 3, and 95 days for stage 4 (log rank test <0.0001).
DISCUSSION
In MM, the importance of S 2M has led to the introduc-
tion of the SWOG staging system. In an attempt to deter-
mine the relationship between S 2M and kidney function
and to choose a more significant prognostic factor, we were
unable to find any study that included both 24 hr urinary
Ccr and S 2M as prognostic factors. Thus, to our knowledge,
this study is the first to include both of these as prognostic
factors.
We found that in MM, S 2M and Ccr were more closely
related than we expected. Multivariate analysis showed that
S 2M, Ccr, and treatment modalities were independent prog-
nostic factors. Thus, the results of this study suggest that Ccr
is a new, powerful prognostic factor in the patients with MM.
Moreover, this finding indicates that Ccr can be incorporat-
ed into a discrete new staging system for MM.
It was interesting that S 2M was not significant in patients
whose Ccr was greater than 30 mL/min. That is, the incre-
mental addition of S 2M concentration was not a significant
prognostic factor if kidney function was relatively good. Thus,
the effect of S 2M on patient survival might be mainly due
to declining kidney function.
Our new staging system used Ccr instead of S 2M. The
latter is not likely to be a specific tumor marker in MM. This
finding indicates that patient survival is related to the dec-
reased excretion of S 2M rather than to its overproduction.
There is evidence that S 2M reflects glomerular filtration rate
in many situations, although it also reflects tumor cell mass
(9-11). Although our Kaplan-Meier curves of stages relative
to Ccr and serum albumin concentrations were discrete, they
were unable to show that Ccr was a more significant prognos-
tic factor than S 2M. These two factors, plus serum creatinine,
are related, and other conflicting factors affect survival, thus
making interpretation difficult. Differences in mean Ccr bet-
ween patients with both heavy and light chains and those
with only free light chains may be related to different sur-
vival times. Although the SWOG staging system has been
regarded as easier and likely to supersede the DS staging sys-
tem, it is cautious to determine the superiority between the
two staging systems. Serum albumin was not a significant
prognostic in univariate analysis, but, in the SWOG staging
system, it was important in sorting patients with advanced
stage MM.
Our study had several limitations. First, we may have in-
cluded patients who died accidentally, since the causes of death
of patients who died outside the hospital could not be deter-
mined. Second, this retrospective study did not include im-
portant parameters such as performance status, C reactive
protein, chromosome 13 abnormality, and plasma cell label-
ing index (12, 13).
In conclusion, we found that in patients with MM, S 2M
was an independent significant prognostic factor in multiva-
riate analysis that included Ccr. Although closely related to
S 2M, Ccr was also a significant prognostic factor that could
replace S 2M in staging systems of MM. Mean Ccr differed
among heavy chain types, and these differences were likely
related to different survival times. 
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